Responses
Clinical/translational cancer immunotherapy
Original research
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
Compose a Response to This Article
Other responses
No responses have been published for this article.